The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Co-expression network-based analysis of gene programs contributing to immune checkpoint inhibitor (ICI) resistance in renal cell carcinoma (RCC).
 
Ro Malik
No Relationships to Disclose
 
Rishabh Rout
No Relationships to Disclose
 
Soki Kashima
No Relationships to Disclose
 
Eddy Saad
Research Funding - EMD Serono; Genentech/Roche (Inst); Oncohost
 
Harry Kane
No Relationships to Disclose
 
Valisha Shah
No Relationships to Disclose
 
Miya Hugaboom
No Relationships to Disclose
 
Zhaochen Ye
No Relationships to Disclose
 
Nicholas Schindler
No Relationships to Disclose
 
Anasuya Dighe
No Relationships to Disclose
 
Maxine Sun
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis
 
Gwo-Shu Lee
No Relationships to Disclose
 
Wenxin Xu
Consulting or Advisory Role - Aveo; Celdara Medical; Deciphera; Eisai; Exelixis; Jazz Pharmaceuticals; Merck; Xencor
Research Funding - ArsenalBio (Inst); Merck (Inst); Oncohost (Inst)
 
Sabina Signoretti
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; crispr therapeutics; Merck; Nextpoint
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech (Inst); Merck (Inst); NiKang Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Receives royalties from Biogenex
Other Relationship - AACR; NCI
 
Bradley McGregor
Consulting or Advisory Role - Arcus Biosciences; Astellas Pharma; AVEO; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Eisai; Exelixis; Genmab; Gilead Sciences; Hexagon; Loxo/Lilly; Pfizer; Seattle Genetics/Astellas
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Pfizer/EMD Serono (Inst); Seattle Genetics/Astellas (Inst)
 
Rana McKay
Consulting or Advisory Role - Ambrx; Arcus Biosciences; Astellas Medivation; AstraZeneca; AVEO; Bayer; Blue Earth Diagnostics; Bristol Myers Squibb; Calithera Biosciences; Caris Life Sciences; Daiichi Sankyo; Dendreon; Esiai; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; NeoMorph; Novartis; Pfizer; Sanofi; Seagen; Sorrento Therapeutics; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Artera (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Exelixis (Inst); Oncternal Therapeutics (Inst); Tempus (Inst)
 
Michael Atkins
Leadership - Werewolf Therapeutics
Stock and Other Ownership Interests - Pyxis; Werewolf Pharma
Consulting or Advisory Role - 23AndMe; Abbvie; Agenus; AstraZeneca; Aveo; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Innovent Biologics; IO Biotech; Jazz Pharmaceuticals; Merck; Novartis; Oncorena; Pfizer; Pliant; Pyxis; Replimune; Sanofi; Simcha Therapeutics; Syncona; Werewolf Pharma
Research Funding - Agenus (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - BMS Canada; BMS Sweden
 
Eliezer Van Allen
Stock and Other Ownership Interests - ervaxx; Genome Medical; Genomic Life; Manifold Bio; Microsoft; Monte Rosa Therapeutics; Riva Therapeutics; Serinus Bio; Syapse; Tango Therapeutics
Consulting or Advisory Role - ervaxx; Genome Medical; Genomic Life; Illumina; Janssen; Manifold Bio; Monte Rosa Therapeutics; Novartis; Riva Therapeutics; Serinus Bio; Syapse; Tango Therapeutics; Tracer Bio
Speakers' Bureau - Illumina; TD Cowen
Research Funding - Bristol-Myers Squibb; Nextpoint (Inst); Novartis; Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Patent on clinical interpretation algorithms using cancer molecular data (Inst); Patent on discovery of chromatin regulators as biomarkers of response to cancer immunotherapy (Inst); Patent on discovery of retained intron as source of cancer neoantigens (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Toni Choueiri
Leadership - ASCO
Stock and Other Ownership Interests - Abalytics Oncology; Bicycle Therapeutics; Curesponse; Faron Pharmaceuticals; Inndura; Osel; Pionyr; Precede Bio; Primium; Tempest Therapeutics
Honoraria - Alkermes; Analysis Group; Aravive; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinical Care Options; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; HiberCell; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; MashupMD; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - alkermes; Analysis Group; Aravive; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bicycle Therapeutics; Bristol-Myers Squibb; Clinical Care Options; Curesponse; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Neomorph; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy (Inst); ctDNA technologies; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - OTHER MEDICAL COMMUNICATION COMPANIES
 
David Braun
Stock and Other Ownership Interests - CurIOS Therapeutics; Elephas Bio; Fortress Biotech (subsidiary)
Consulting or Advisory Role - 2nd.MD; Abbvie; Adept Field Solutions; Aptitude Health; AVEO; Blueprint Partnership; Bristol-Myers Squibb; Catenion; Cello Health; Charles River Associates; Compugen; CurIOS Therapeutics; Daiichi Sankyo; Dedham Group; Defined Health; DLA Piper; Eisai; Eisai; Elephas Bio; Exelixis; GU Oncology Now; Insight Strategy; Link Cell Therapies; Merck; Neomorph; Nimbus Therapeutics; Octane Co.; Pfizer; Pfizer; Schlesinger Associates; Scholar Rock; Scholar Rock; Scholar Rock; Scholar Rock; SignifyMD; Slingshot Insights; Targeted Oncology; Trinity Group
Research Funding - AstraZeneca; Exelixis
Travel, Accommodations, Expenses - Bristol-Myers Squibb